-
Wawrinka falls in first round of Monte Carlo Masters
-
Ex-England rugby international Lawes to leave Brive
-
Fit-again Mbappe at Real Madrid for clashes like Bayern tie: Arbeloa
-
Swimmers McKeown, O'Callaghan and Chalmers dominate at Australian Open
-
Bucha: When the Russian killers came...
-
Iran, a Terrorist State with No Right to Exist
-
African players in Europe: Semenyo scores as City rout Liverpool
-
Israeli strikes kill Iran Guards intel chief as Trump deadline looms
-
Saving energy in everyday life or a complete rip-off?
-
US sprint star Richardson wins Australia's Stawell Gift in record time
-
Rockets down Warriors in Curry return, Flagg carries Mavs past Lakers
-
Artemis mission approaches lunar loop for first flyby since 1972
-
Israeli rescuers search for missing in building strike, two dead
-
Defiant Iran ramps up attacks after Trump warning
-
Saudi oasis town adjusts to life in the firing line
-
Pogacar stays humble with Monument history beckoning
-
Real Madrid hoping Champions League magic halts Bayern juggernaut
-
Sputtering Arsenal face test of character in Sporting clash
-
'Not the Cairo we know': Energy shock from Iran war dims Egypt nights
-
Tokyo, Seoul shares gain, war sends oil higher
-
Artemis mission headed for first lunar flyby since 1972
-
South Korea president says regrets 'reckless' drones sent to North
-
Coughlin captures third LPGA title at Aramco Championship
-
What to know about the Artemis 2 mission's Moon flyby
-
Mystique of the green jacket endures as Masters looms
-
In El Salvador's mass trials, 'the innocent pay for the guilty'
-
Trump makes stark threat to Iran after US airman rescued
-
Datavault AI CEO Nathaniel T. Bradley to Deliver Flagship Keynotes on Breakthrough RWA Tokenization at CONV3RGENCE London and AssetRush × Zurich 2026
-
HarrisQuest Launches Lou, a Voice-Enabled AI Analyst Built Inside The Harris Poll's Brand Tracking Platform
-
Fortitude Gold Declares April 2026 Monthly Dividend
-
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board
-
Arrive AI Secures Tenth U.S. Patent, Positioning as the Critical Infrastructure Layer for Autonomous Delivery at Scale
-
National Study of 2,300+ Women Finds Social Connection Shapes Volunteer Experience Amid Competing Work, Caregiving, and Life Demands
-
Prof. Abdul Al Lily Announces the Release of The Naughty AI CEO, Exploring the Future of AI-Driven Leadership
-
Hillcrest Closes Shares for Debt Offering
-
Elektros Positions Itself at the Center of High-Stakes EV Infrastructure Opportunity Through Strategic Engagement with Major Global Automotive Leader
-
ReElement Technologies Announces April Conference and Event Schedule
-
Greenpro Capital Corp. Successfully Acquires Stake in AI Forekast Limited, an Augmented Intelligence Provider
-
Ondas' 4M Defense Wins Competitive Tender for Large-Scale Border Demining Program with Opportunity Expected to Exceed $50 Million
-
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
-
MDCE's Snapshot Recipes App Scales Marketing Strategy Beyond Initial Podcast Deals with Expanded iHeart Campaign
-
SMX Announces Launch of Its Digital Material Passport Platform, Enabling Real-World Asset Tokenisation and Global Material Traceability
-
Bora Biologics Successfully Completes 2,000L Engineering and Scale-Up Run in San Diego, Reinforcing Commercial-Scale Readiness
-
Avino Announces Normal Course Issuer Bid for Common Shares
-
Revolve Signs Interconnection Agreement for 130 MW EL 24 Wind Project in Mexico
-
Building the Moon's Future: Helio Positioned at the Center of America's Lunar Strategy for the Dawn of the Artemis Era
-
Trumps FDA CBD Enforcement Shift Signals a Turning Point - Why MMJ International Holdings is the Sector's Opportunity
-
Amphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare Conference
-
Texas Gulf Bank, N.A. Appoints Chase Zalman President
-
Bioz and Vilber Advance Evidence-Driven Scientific Marketing with Custom Publication Integration
Google unveils AI tool probing mysteries of human genome
Google unveiled an artificial intelligence tool Wednesday that its scientists said would help unravel the mysteries of the human genome -- and could one day lead to new treatments for diseases.
The deep learning model AlphaGenome was hailed by outside researchers as a "breakthrough" that would let scientists study and even simulate the roots of difficult-to-treat genetic diseases.
While the first complete map of the human genome in 2003 "gave us the book of life, reading it remained a challenge", Pushmeet Kohli, vice president of research at Google DeepMind, told journalists.
"We have the text," he said, which is a sequence of three billion nucleotide pairs represented by the letters A, T, C and G that make up DNA.
However "understanding the grammar of this genome -- what is encoded in our DNA and how it governs life -- is the next critical frontier for research," said Kohli, co-author of a new study in the journal Nature.
Only around two percent of our DNA contains instructions for making proteins, which are the molecules that build and run the body.
The other 98 percent was long dismissed as "junk DNA" as scientists struggled to understand what it was for.
However this "non-coding DNA" is now believed to act like a conductor, directing how genetic information works in each of our cells.
These sequences also contain many variants that have been associated with diseases. It is these sequences that AlphaGenome is aiming to understand.
- A million letters -
The project is just one part of Google's AI-powered scientific work, which also includes AlphaFold, the winner of 2024's chemistry Nobel.
AlphaGenome's model was trained on data from public projects that measured non-coding DNA across hundreds of different cell and tissue types in humans and mice.
The tool is able to analyse long DNA sequences then predict how each nucleotide pair will influence different biological processes within the cell.
This includes whether genes start and stop and how much RNA -- molecules which transmit genetic instructions inside cells -- is produced.
Other models already exist that have a similar aim. However they have to compromise, either by analysing far shorter DNA sequences or decreasing how detailed their predictions are, known as resolution.
DeepMind scientist and lead study author Ziga Avsec said that long sequences -- up to a million DNA letters long -- were "required to understand the full regulatory environment of a single gene".
And the high resolution of the model allows scientists to study the impact of genetic variants by comparing the differences between mutated and non-mutated sequences.
"AlphaGenome can accelerate our understanding of the genome by helping to map where the functional elements are and what their roles are on a molecular level," study co-author Natasha Latysheva said.
The model has already been tested by 3,000 scientists across 160 countries and is open for anyone to use for non-commercial reasons, Google said.
"We hope researchers will extend it with more data," Kohli added.
- 'Breakthrough' -
Ben Lehner, a researcher at Cambridge University who was not involved in developing AlphaGenome but did test it, said the model "does indeed perform very well".
"Identifying the precise differences in our genomes that make us more or less likely to develop thousands of diseases is a key step towards developing better therapeutics," he explained.
However AlphaGenome "is far from perfect and there is still a lot of work to do", he added.
"AI models are only as good as the data used to train them" and the existing data is not very suitable, he said.
Robert Goldstone, head of genomics at the UK's Francis Crick Institute, cautioned that AlphaGenome was "not a magic bullet for all biological questions".
This was partly because "gene expression is influenced by complex environmental factors that the model cannot see", he said.
However the tool still represented a "breakthrough" that would allow scientists to "study and simulate the genetic roots of complex disease", Goldstone added.
H.Thompson--AT